GlassScriptPhysician profile
James H Mersey
NPI 1669477683
$36,886.94
in general payments reported to CMS, 2019-2025
41 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $2,822 · 2021: $8,876 · 2022: $3,328 · 2023: $1,283 · 2024: $1,527 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,270.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26,668.28 | 2019-2023 | |
| Amgen INC. | $1,484.84 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $1,255.27 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $1,189.92 | 2021-2024 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $828.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $703.18 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $566.95 | 2021-2024 | Nexletol |
| Dexcom, INC. | $503.42 | 2019-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Corcept Therapeutics | $443.05 | 2020-2023 | Korlym |
| Horizon Therapeutics Plc | $313.68 | 2021-2022 | |
| Radius Health, INC. | $292.82 | 2019-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.18 | 2022-2024 | Jardiance |
| Abbvie INC. | $249.57 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $236.51 | 2021-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $211.34 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mersey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.